ENDONOVO THERAPEUTICS, INC. Operating Income

Quick Answer

ENDONOVO THERAPEUTICS, INC. reported Operating Income of -$3.26 million for fiscal year 2022.

ENDONOVO THERAPEUTICS, INC. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2022 -$3.26M -46.6%
2021 -$2.23M +23.5%
2020 -$2.91M +23.5%
2019 -$3.81M +8.4%
2018 -$4.16M +9.7%
2017 -$4.60M +14.9%
2016 -$5.41M -111.0%
2015 -$2.56M -17.0%
2014 -$2.19M -2193.9%
2011 -$95.5K -22.5%
2010 -$78.0K

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2023 -$472.8K +4.8% +58.2%
June 30, 2023 -$1.13M +37.1% -113.7%
March 31, 2023 -$529.3K -9.0% -6.5%
September 30, 2022 -$496.8K +28.2% +72.4%
June 30, 2022 -$1.80M -215.5% -270.3%
March 31, 2022 -$485.8K +17.7% +29.8%
September 30, 2021 -$692.3K +26.9% -21.4%
June 30, 2021 -$570.1K +5.3% +3.5%
  • ENDONOVO THERAPEUTICS, INC. showed a decrease of -46.6% in Operating Income compared to the prior fiscal year.
  • Over the 2010–2022 period, ENDONOVO THERAPEUTICS, INC.’s operating income has declined by 4085.8% (from -$78.0 thousand to -$3.26 million).
  • The most recent figure is from ENDONOVO THERAPEUTICS, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on April 17, 2023.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment